Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds

Rexahn Pharmaceuticals, Inc.

today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled “Quinazoline Derivatives and Therapeutic Use Thereof.” This new patent covers Rexahn's anti-cancer candidate RX-1792 and related compounds, and a composition for treating anti-proliferative and anti-tumor activities. Rick Soni, President of Rexahn, noted, “We are very pleased to obtain this additional patent coverage for RX-1792 in Japan, which broadens and strengthens our global intellectual property position. RX-1792 continues to demonstrate exciting anti-proliferative and anti-tumor effects in preclinical studies, and we look forward to accelerating its development.”